Cargando…

Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study

Xanthine oxidoreductase (XOR) and its products contribute to the development of chronic inflammation and oxidative stress. Excessive XOR activity is believed to promote inflammatory responses and atherosclerotic plaque formation, which are major cardiovascular risk factors. The mechanisms of XOR act...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotozaki, Yuka, Satoh, Mamoru, Nasu, Takahito, Tanno, Kozo, Tanaka, Fumitaka, Sasaki, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045414/
https://www.ncbi.nlm.nih.gov/pubmed/36979733
http://dx.doi.org/10.3390/biomedicines11030754
_version_ 1784913597911007232
author Kotozaki, Yuka
Satoh, Mamoru
Nasu, Takahito
Tanno, Kozo
Tanaka, Fumitaka
Sasaki, Makoto
author_facet Kotozaki, Yuka
Satoh, Mamoru
Nasu, Takahito
Tanno, Kozo
Tanaka, Fumitaka
Sasaki, Makoto
author_sort Kotozaki, Yuka
collection PubMed
description Xanthine oxidoreductase (XOR) and its products contribute to the development of chronic inflammation and oxidative stress. Excessive XOR activity is believed to promote inflammatory responses and atherosclerotic plaque formation, which are major cardiovascular risk factors. The mechanisms of XOR activity in the development and progression of cardiovascular disease (CVD), coupled with the complexity of the relationship between XOR activity and the biological effects of uric acid; reactive oxygen species; and nitric oxide, which are the major products of XOR activity, have long been debated, but have not yet been clearly elucidated. Recently, a system for measuring highly sensitive XOR activity in human plasma was established, and there has been progress in the research on the mechanisms of XOR activity. In addition, there are accumulating findings about the relationship between XOR activity and CVD. In this narrative review, we summarize existing knowledge regarding plasma XOR activity and its relationship with CVD and discuss future perspectives.
format Online
Article
Text
id pubmed-10045414
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100454142023-03-29 Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study Kotozaki, Yuka Satoh, Mamoru Nasu, Takahito Tanno, Kozo Tanaka, Fumitaka Sasaki, Makoto Biomedicines Review Xanthine oxidoreductase (XOR) and its products contribute to the development of chronic inflammation and oxidative stress. Excessive XOR activity is believed to promote inflammatory responses and atherosclerotic plaque formation, which are major cardiovascular risk factors. The mechanisms of XOR activity in the development and progression of cardiovascular disease (CVD), coupled with the complexity of the relationship between XOR activity and the biological effects of uric acid; reactive oxygen species; and nitric oxide, which are the major products of XOR activity, have long been debated, but have not yet been clearly elucidated. Recently, a system for measuring highly sensitive XOR activity in human plasma was established, and there has been progress in the research on the mechanisms of XOR activity. In addition, there are accumulating findings about the relationship between XOR activity and CVD. In this narrative review, we summarize existing knowledge regarding plasma XOR activity and its relationship with CVD and discuss future perspectives. MDPI 2023-03-01 /pmc/articles/PMC10045414/ /pubmed/36979733 http://dx.doi.org/10.3390/biomedicines11030754 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kotozaki, Yuka
Satoh, Mamoru
Nasu, Takahito
Tanno, Kozo
Tanaka, Fumitaka
Sasaki, Makoto
Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study
title Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study
title_full Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study
title_fullStr Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study
title_full_unstemmed Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study
title_short Human Plasma Xanthine Oxidoreductase Activity in Cardiovascular Disease: Evidence from a Population-Based Study
title_sort human plasma xanthine oxidoreductase activity in cardiovascular disease: evidence from a population-based study
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045414/
https://www.ncbi.nlm.nih.gov/pubmed/36979733
http://dx.doi.org/10.3390/biomedicines11030754
work_keys_str_mv AT kotozakiyuka humanplasmaxanthineoxidoreductaseactivityincardiovasculardiseaseevidencefromapopulationbasedstudy
AT satohmamoru humanplasmaxanthineoxidoreductaseactivityincardiovasculardiseaseevidencefromapopulationbasedstudy
AT nasutakahito humanplasmaxanthineoxidoreductaseactivityincardiovasculardiseaseevidencefromapopulationbasedstudy
AT tannokozo humanplasmaxanthineoxidoreductaseactivityincardiovasculardiseaseevidencefromapopulationbasedstudy
AT tanakafumitaka humanplasmaxanthineoxidoreductaseactivityincardiovasculardiseaseevidencefromapopulationbasedstudy
AT sasakimakoto humanplasmaxanthineoxidoreductaseactivityincardiovasculardiseaseevidencefromapopulationbasedstudy